AACE guideline provides evidence-based recommendations for NAFLD/NASH diagnosis and management in primary care and endocrinology. Its cirrhosis-prevention algorithm advises referring patients at indeterminate or high fibrosis risk for specialist evaluation using advanced noninvasive biomarkers, including cT1 (LiverMultiScan), to refine staging and guide care.